Clinical trial · Interventional
Vaccination With Dendritic Cell/Tumor Fusions With Autologous Stem Cell Transplants in Patients With Multiple Myeloma
Vaccination With Dendritic Cell/Tumor Fusions in Conjunction With Autologous Stem Cell Transplant in Patients With Multiple Myeloma
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The main purpose of this study is to test the safety and determine the type and severity of any side effects of the Dendritic Cell Fusion Vaccine given in combination with an autologous transplant for patients with multiple myeloma. Autologous stem cell transplantation is a standard therapy for multiple myeloma that is often successful in significantly decreasing the amount of cancer. However, it is not a cure because at some point the multiple myeloma generally begins to grow again. Cancer vaccines are investigational agents that try to stimulate the immune system to recognize and fight against cancer cells. One type of cancer vaccine uses an immune stimulating cell of the body known as a dendritic cell. Research has shown that these dendritic cells can stimulate an immune response against the tumor.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Multiple Myeloma | Multiple Myeloma | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Dendritic Cell Tumor Fusion | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Group A
- description
- Post-transplant vaccination
- interventionNames
- Biological: Dendritic Cell Tumor Fusion
- type
- EXPERIMENTAL
- label
- Group B
- description
- Pre- and post-transplant vaccination
- interventionNames
- Biological: Dendritic Cell Tumor Fusion
Primary outcomes (1)
- measure
- To assess the toxicity associated with vaccination of multiple myeloma patients with dendritic cell/myeloma fusions and GM-CSF prior to stem cell mobilization and following high dose chemotherapy with stem cell rescue.
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with multiple myeloma who are potential candidates for high dose chemotherapy * Measurable disease as defined by a history of an elevated M component in plasma, urine, or free kappa/lambda light chains in the serum * 18 years of age or older * ECOG Performance Status of 0-1 with greater than a nine week life expectancy * Patients with \> 20% bone marrow involvement or plasmacytoma amenable to resection under local anesthesia * Negative pregnancy test, and adequate contraception method * DLCO (adjusted)\> 50% * Cardiac Ejection Fraction \> 45% * Laboratory values within the ranges outlined in the protocol Exclusion Criteria: * History of clinically significant venous thromboembolism * Clinically significant autoimmune disease * HIV positive * Serious intercurrent illness such as infection requiring IV antibiotics, or significant cardiac disease characterized by significant arrhythmia, ischemic coronary disease or congestive heart failure * Pregnant or lactating women
References
Publications (0)
Data not yet available